ioversol has been researched along with bucladesine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itoh, Y; Kubota, T; Oishi, R; Sendo, T; Yano, T | 1 |
| Fujita, T; Itoh, Y; Koyama, T; Kubota, T; Oishi, R; Saeki, K; Sendo, T; Yano, T; Yuo, A | 1 |
2 other study(ies) available for ioversol and bucladesine
| Article | Year |
|---|---|
Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Bucladesine; Caspases; Cell Survival; Contrast Media; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Iodine Radioisotopes; Kidney Tubules, Proximal; LLC-PK1 Cells; Osmolar Concentration; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Swine; Time Factors; Triiodobenzoic Acids | 2003 |
A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein.
Topics: Animals; Apoptosis; Bucladesine; Caspases; Cell Survival; Contrast Media; Cyclic AMP Response Element-Binding Protein; Enzyme Activation; Epoprostenol; Kidney; Kidney Diseases; LLC-PK1 Cells; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotransferases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Swine; Triiodobenzoic Acids | 2005 |